Yifan Pharmaceutical Co., Ltd. Class A
SSZSE:0020199.36
CNY
+0.16
(+1.74%)
ISIN
CNE000001K65
Return %
Stock
S&P 500
1Y
-27.72
13.14
3Y
-25.95
80.78
5Y
-40.61
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xian Feng Cheng
- Full Time Employees
- 4,221
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 50, Qinshan Hangzhou ZH China 311300
- IPO Date
- Jul 13, 2004
- Website
- yifanyy.com
- Similar Companies
- Business
- Yifan Pharmaceutical Co., Ltd. (002019.SZ) is a China-based innovative research, development, production and sales company focused on pharmaceuticals and healthcare products. The company engages in the R&D, manufacturing and commercialization of macromolecules including recombinant human insulin injections, recombinant human growth hormone for injection and ibergestine alpha injections; small molecules such as capecitabine tablets, ganciclovir hydrochloride tablets, vincristine sulfate injections and clofarabine injections; synthetic biologics encompassing metabolic peptides like teriparatide, semaglutide and liraglutide alongside special raw materials and excipients for vitamins, antivirals, cytotoxics and contrast agents; and special traditional Chinese medicines (TCMs) comprising pediatric qingiao granules, compound silver flower detoxifying granules and maqin cough relief granules. It operates advanced production platforms for oral slow/controlled release preparations, micron suspensions, micelles for injection and high-end complex liquid preparations, with dozens of cGMP-compliant industrial bases supporting therapeutic areas such as hematologic malignancies, inflammation, endocrinology/metabolism, dermatology, gynecology and pediatrics; it also provides CDMO services for biologics, peptides and APIs. Founded in 2003 and headquartered in Hangzhou, Zhejiang Province, China, Yifan Pharmaceutical conducts business across more than 40 countries and regions in Southeast Asia, Europe and North America, including Singapore, South Korea, Italy, Germany and the United States. Recent developments include the 2024-2025 global commercialization of its innovative biologic Elyso (Abegeptin Alpha Injection), with approvals in 34 countries, commercial shipments in five including the United States, and expanded partnerships such as with Acrotech for increased U.S. purchase orders exceeding 40,000 units in 2025, Zhejiang Hisun Pharmaceuticals and others covering China, Europe and beyond; in-licensing deals for Nilotinib Capsules with Phar OS in Colombia/Central America, Abiraterone Tablets with Novugen in Mexico/Central America and Dydrogesterone Tablets with Mankind in the Philippines; exclusive marketing rights from Bayer China for Stivarga (Regorafenib Tablets) and Nexavar (Sorafenib); out-licensing of Oxytocin Nasal Spray to Sygardis Rus in Russia; and launches of Ryzneuta (efbemalenograstim alfa) in Germany via APOGEPHA and in Central/Eastern Europe via Lenis Group, alongside over 478% shipment growth for imported Diclofenac Sodium Hyaluronate Injection (Yini Kang). The company listed on the Shenzhen Stock Exchange main board in 2014, changed its name from Yifan Xinfu Pharmaceutical in 2016 and established a Global Business Development center in H1 2025 to drive in/out-licensing and overseas expansion.